Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations(25 sites)
United States
Neurology of Central Florida Research Center, LLC, Altamonte Springs, Florida SFM Clinical Research, LLC, Boca Raton, Florida Aqualane Clinical Research, Naples, Florida Medsol Clinical Research Center, Port Charlotte, Florida University of South Florida, Tampa, Florida University of Kansas Medical Center Research Institute, Inc., Kansas City, Missouri Nerve & Muscle Center of Texas, Houston, Texas Houston Methodist Neurological Institute, Houston, Texas Bulgaria
Medical Center Hera - branch Montana, Montana "MHAT Avis - Medica" OOD, Pleven UMHAT 'Dr. Georgi Stranski', EAD, Pleven UMHAT 'Tsaritsa Yoanna - ISUL', EAD, Sofia Haelan Care 4 Medical Center EOOD, Varna Italy
Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia (Presidio Spedali Civili), Brescia, Brescia Ospedale San Raffaele, Milan, Milano Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Milano Poland
Neurologia Slaska Centrum Medyczne, Katowice Twoja Przychodnia NCM, Nowa Sól Twoja Przychodnia PCM, Poznan NZOZ Neuro-Kard Ilkowski i Partnerzy Spółka Partnerska Lekarzy, Poznan Samodzielny Publiczny Szpital Kliniczny nr 1 im. Prof. Stanislawa Szyszko, SUM, Zabrze Serbia
General Hospital MSB Medical System Belgrade, Belgrade Spain
Hospital Universitario Clinico San Carlos, Madrid, Madrid Hospital Universitario La Paz, Madrid, Madrid Clinica Universidad de Navarra, Pamplona, Navarre